Cite
HARVARD Citation
Luo, J. et al. (2022). De‐escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open‐label, prospective trial in China. EJHaem. 3 (4), pp. 1220-1230. [Online].